Skip to content
★ Sign in to follow
S.Biomedics Co., Ltd. logo

S.Biomedics Co., Ltd. Stock: price and insider trades · South Korea

에스바이오메딕스

KR·Mcap ₩237.7BHealth Care

No insider purchase over the last 90 days. The latest, by 타이거자산운용투자일임, was filed 22 Apr 2026.

Insider Decl.
28
Thresholds
n/a
Buy Volume
€17M
11 ops. · all time
Sell Volume
€103M
13 ops. · all time

Who traded when

BuySale
Kang Saeil3 sales
타이거자산운용투자일임1 buy

Since the insiders bought

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 23,226 of 26,913 companies
25.4
score / 100
Value
24
Quality
26
FCF yld-3.8%
Earn yld-3.7%
EV/EBITDA·
ROE-39%
Gross mgn46%
Net mgn-49%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩19,190
Analyst consensus
·
Income statement
Revenue₩16.5B
Gross profit₩7.5B46% margin
EBITDA-₩3.3B-20% margin
Net income-₩8.1B-73.1% margin
Valuation
Beta1.46
Balance sheet & cash
Market cap₩237.7B
Total debt₩12.2B
Free Cash Flow-₩8.4B
Debt / Equity51%
Profitability & ownership
ROE-39.3%
ROA-11.9%
% insiders22.4%
% institutions1.1%
Last declaration on 31 August 2026
Declarations31 total
  • ▼
    대표이사Executives(filed)
    €99kest.0DART
    8,000 sharesShareKRXDART:20260831001343
  • Other
    Other(filed)
    0DART
  • ▲
    Related company / holdingExecutives
    €16.8Mest.0DART
    887,988 sharesKRXDART:20260422000428
    Canonical exit: 14 Jul 2026 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    Executives
    €17kest.0DART
    700 sharesKRXDART:20260109000225
  • ●
    Executives
    Executives
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ▼
    대량보유자Executives
    €875kest.0DART
    69,764 sharesKRXDART:20250604000033
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    Executives
    €1.3Mest.0DART
    114,500 sharesKRXDART:20241210000453
  • ▼
    Executives
    €5.1Mest.0DART
    225,452 sharesKRXDART:20240812000873
  • ▲
    전무Executives
    0DART
    ShareKRXDART:20240614000024
    Canonical exit: 9 Sept 2024 (T+90)
  • ▼
    Executives
    €25.4Mest.0DART
    893,345 sharesKRXDART:20240614000254
  • ▲
    대표이사Executives
    0DART
    ShareKRXDART:20240614000252
    Canonical exit: 9 Sept 2024 (T+90)
  • ▲
    기타비상무이사Executives
    0DART
    ShareKRXDART:20240613000123
    Canonical exit: 9 Sept 2024 (T+90)
  • ▲
    상무Executives
    0DART
    ShareKRXDART:20240613000093
    Canonical exit: 9 Sept 2024 (T+90)
  • ▼
    Executives
    €25.1Mest.0DART
    893,345 sharesKRXDART:20240510000749
  • ▼
    대량보유자Executives
    0DART
    2,062,480 sharesKRXDART:20240503000527
  • ▲
    상무Executives
    0DART
    ShareKRXDART:20231218000068
    Canonical exit: 14 Mar 2024 (T+90)
  • ▼
    Executives
    €6.2Mest.0DART
    893,345 sharesKRXDART:20230810000896
  • ▲
    상무Executives
    0DART
    ShareKRXDART:20230808000043
    Canonical exit: 6 Nov 2023 (T+90)
  • ▼
    Executives
    €5.5Mest.0DART
    893,345 sharesKRXDART:20230801000249
  • ▲
    상무Executives
    0DART
    ShareKRXDART:20230630000478
    Canonical exit: 26 Sept 2023 (T+90)

25 of 31 declarations

About S.Biomedics Co., Ltd.

At 에스바이오메딕스 (S.Biomedics Co., Ltd.), a South Korean health care company listed on the Korea Exchange, sales slightly outnumber purchases: 13 against 11, or 46% purchases among open-market trades. Market capitalisation is KRW 261.9 billion and insiders hold 22.4% of the capital.

Kang Saeil, filed as 대표이사, made 12 filings, 10 of them sales and 1 a purchase. 나현섭 (상무) has 7, all purchases, and 바이넥스, filed as 대량보유자, has 3 sales. On June 11, 2024, 4 filers bought on the same day, the busiest buying window in the record.

Read moreShow less

In all, 7 filers published 28 filings between May 4, 2023 and August 31, 2026, 4 of them of another kind. The year 2023 has 11 filings and 2024 has 9, against 3 in 2025 and 5 in 2026. They are published a median of 4 days after the trade. Over the last twelve months there are 5, of which 1 purchase and 2 sales.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations